Format

Send to

Choose Destination
Clin Pharmacol Ther. 2010 Nov;88(5):708-11. doi: 10.1038/clpt.2010.185. Epub 2010 Sep 29.

Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection.

Author information

1
Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA. paul.clark@duke.edu

Abstract

As more pharmacogenomic insights into diseases and their treatments and toxicities are published each year, the challenge arises to incorporate such insights into clinical practice and drug development. For instance, recent genomic discoveries related to hepatitis C offer a challenge to clinicians, researchers,and health administrators to translate this information into knowledge in order to develop safer and more effective therapeutic strategies for all patients.

PMID:
20881951
DOI:
10.1038/clpt.2010.185
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center